MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
MLTX moved a median of +0.15% 30 minutes after news, and +0.20% by the close. How MLTX actually reacts to news — the realized, point-in-time move the market made, measured across 1,186 labeled events over the last three years with zero look-ahead.
MLTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.10% | 54% | 1,182 |
| 30-min | +0.15% | 52% | 1,184 |
| 60-min | -0.20% | 47% | 1,184 |
| to close | +0.20% | 53% | 1,164 |
| Middle 50% of MLTX reactions | -0.97% to +1.27% |
|---|---|
| Median reaction (30-min) | +0.15% |
| Measured reactions | 1,186 |
Half of all MoonLake Immunotherapeutics - Class A Ordinary Shares news events land between -0.97% and +1.27% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MLTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 22 | -0.82% | 27% | -0.71% |
| Analyst downgrades | 29 | -0.47% | 48% | -0.27% |
| Coverage initiations | 21 | -1.17% | 33% | -0.96% |
| Rating reiterations | 116 | +0.06% | 51% | -0.09% |
| Price-target raises | 14 | -0.15% | 36% | -0.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how MLTX ranks against every other measured name →
That’s how MLTX usually reacts — get an email when it moves on news →Email me when MLTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MLTX's baseline. Nothing else.
Recent MLTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K MoonLake Immunotherapeut For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -2.22% | |
| Form 10-Q MoonLake Immunotherapeut For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.76% | — | |
| Form 8-K MoonLake Immunotherapeut For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -0.76% | — | |
| Form 8-K MoonLake Immunotherapeut For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +2.67% | |
| Form 8-K MoonLake Immunotherapeut For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -1.67% | |
| MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering | Press release | GlobeNewswire | +0.54% | +3.15% | |
| Form 8-K MoonLake Immunotherapeut For: Jun 21 | SEC filing · Form 8-K | SEC EDGAR | +6.32% | +11.53% | |
| MoonLake Immunotherapeutics Announces Proposed Public Offering | Press release | GlobeNewswire | +0.14% | +1.68% | |
| MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 | Press release | GlobeNewswire | +6.32% | +11.53% | |
| Form 8-K MoonLake Immunotherapeut For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | -1.13% | |
| Form 8-K MoonLake Immunotherapeut For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +0.48% | |
| Form 10-Q MoonLake Immunotherapeut For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.29% | |
| Form 8-K MoonLake Immunotherapeut For: May 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.29% | |
| Form ARS MoonLake Immunotherapeut For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.52% | -1.43% | |
| Form DEF 14A MoonLake Immunotherapeut For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +1.52% | -1.43% | |
| Form DEFA14A MoonLake Immunotherapeut | SEC filing · Form DEFA14A | SEC EDGAR | +1.52% | -1.43% | |
| Form 10-K MoonLake Immunotherapeut For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.92% | +0.66% | |
| Form 8-K MoonLake Immunotherapeut For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -2.56% | -0.37% | |
| MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results | Press release | GlobeNewswire | -2.56% | -0.37% | |
| Form 8-K MoonLake Immunotherapeut For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -11.35% | -11.04% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX | Press release | PR Newswire | -0.54% | -3.18% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | Business Wire | -0.14% | -0.97% | |
| MoonLake Immunotherapeutics (MLTX) Shareholders Get Answers in Latest SueWallSt Podcast | Press release | ACCESS Newswire | -0.18% | +3.86% | |
| DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025 | Press release | PR Newswire | +0.10% | -2.56% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX | Press release | PR Newswire | +0.10% | -2.56% | |
| SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations | Press release | ACCESS Newswire | -0.73% | -2.74% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX | Press release | PR Newswire | +1.38% | +1.07% | |
| SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations | Press release | ACCESS Newswire | +1.38% | +1.07% | |
| MoonLake Immunotherapeutics (MLTX) Shareholders Get Answers in Latest SueWallSt Podcast | Press release | ACCESS Newswire | +0.10% | -1.19% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | GlobeNewswire | +0.10% | -1.19% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX | Press release | PR Newswire | +5.08% | +11.99% | |
| Tune Into the SueWallSt Podcast: MoonLake Immunotherapeutics (MLTX) Lawsuit Explained | Press release | ACCESS Newswire | +5.08% | +11.99% | |
| Tune Into the SueWallSt Podcast: MoonLake Immunotherapeutics (MLTX) Lawsuit Explained | Press release | ACCESS Newswire | +0.40% | +6.12% | |
| Latest SueWallSt Podcast: What MLTX Investors Need to Know About the Lawsuit | Press release | ACCESS Newswire | -1.68% | -4.57% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | GlobeNewswire | -1.68% | -4.57% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX | Press release | PR Newswire | -0.57% | -2.57% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | GlobeNewswire | -0.90% | -1.22% | |
| MLTX DEADLINE: MoonLake Immunotherapeutics Investors are Encouraged to Act before the Upcoming December 15 Deadline - Contact BFA Law if You Lost Money | Press release | ACCESS Newswire | +0.04% | +1.11% | |
| MoonLake Immunotherapeutics (MLTX) Shareholders Get Answers in Latest SueWallSt Podcast | Press release | ACCESS Newswire | +1.17% | +3.11% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | GlobeNewswire | +0.11% | +1.76% | |
| MLTX FRAUD NOTICE: Lose Money on MoonLake Immunotherapeutics? You may have Rights and are Notified to Contact BFA Law before December 15 Deadline | Press release | ACCESS Newswire | -0.08% | +1.15% | |
| MLTX COURT ALERT: MoonLake Immunotherapeutics Investors that Lost Money May have been Affected by Fraud -- Contact BFA Law by December 15 | Press release | GlobeNewswire | +1.10% | +3.22% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX | Press release | PR Newswire | +0.39% | -2.54% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | GlobeNewswire | +0.39% | -2.54% | |
| Latest SueWallSt Podcast: What MLTX Investors Need to Know About the Lawsuit | Press release | ACCESS Newswire | +0.96% | -4.41% | |
| MLTX LEGAL REMINDER: MoonLake Immunotherapeutics Faces Securities Allegations over Drug Trial Results -- Investors Alerted to Contact BFA Law before December 15 | Press release | ACCESS Newswire | +0.96% | -4.41% | |
| MoonLake Immunotherapeutics (MLTX) Shareholders Get Answers in Latest SueWallSt Podcast | Press release | ACCESS Newswire | +0.68% | +1.50% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | GlobeNewswire | +0.27% | +4.04% | |
| MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX | Press release | GlobeNewswire | +1.06% | — | |
| Tune Into the SueWallSt Podcast: MoonLake Immunotherapeutics (MLTX) Lawsuit Explained | Press release | ACCESS Newswire | +1.22% | +7.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MLTX section they belong to.
Where else MLTX is measured.
MLTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MoonLake Immunotherapeutics - Class A Ordinary Shares's median reaction calculated?
Every labeled MLTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,186 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of MLTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MLTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.